Developer of a neural-like stem cell therapeutic products.
Overview
BRAINSTORM CELL THERAPEUTICS LTD. is an Israeli subsidiary of
Click here to request more information, about this company (FOR COLLABORATION IN R&D. ONLY!)
Note - you have to be registered in this server to
request information. If you haven't done so
yet, please register in this server
Your requests will be forwarded to the developer, who
will contact you directly
You can also see the list of
documents you already requested more information about
BrainStorm Cell Therapeutics Inc., an emerging company developing
neural-like cells derived from bone marrow for autologous brain
transplantation in patients with neurodegenerative diseases, such
as Parkinson's disease and Multiple Sclerosis.
The company holds rights to develop and commercialize the
patent-pending technology through an exclusive, worldwide
licensing agreement with Ramot at tel Aviv University Ltd., the
technology transfer company of Tel Aviv University.
BRAINSTORM is developing NurOwn cell therapy products sourced
from adult stem cells for treatment of neurodegenerative
diseases. The company is initially focusing on development of
bone marrow derived neural-like cells for Parkinson`s disease.
BRAINSTORM has chosen to focus on autologous cell therapies,
which use cells from the patients` own bone marrow to repair a
physical dysfunction, since the company believes that this
approach may circumvent many of the safety hurdles and ethical
controversies involved in competing stem cell research.
NurOwn patent pending technology is based on discoveries made by
the team of prominent neurologist, Prof Eldad Melamed, Head of
Neurology at Rabin Medical Center, and expert cell biologist Dr.
Daniel Offen, at the Felsenstein Medical Research Center of
Tel-Aviv University, enabling the differentiation of bone marrow
derived stem cells into functional neurons, as demonstrated in
animal models.
